The primary focus is companies that develop, make, sell or enable Precision Medicines. A critical combination of science and holistic company analysis is key to our stock selection process.

We focus on maximizing returns through a focus on companies, developing, selling, making or enabling Precision Medicine. We prefer multi-asset companies and look for barriers to entry, a strong strategy for the whole value chain and sustainable business models. We control the level of risk inherent in development stage companies through individual position sizes and at the portfolio level. Investing in enablers of Precision Medicine is a key part of our portfolio construction process.

We normally hold 25 to 45 positions with a maximum weight of 10%, targeting mainly companies between $1 billion and $80 billion market cap. The fund is not benchmark oriented, keeps a low turnover in its positions and cash at minimum, usually below 10%. The UCITS Fund launched on 28 February 2023.

Thanks to advances in genomics, computing and biotechnology we can now target medicines to a patient’s specific disease driver, instead of using a one-size-fits-all approach. This change started in the 1990’s but really accelerated from 2010, first in rare genetic disease and certain cancers. There is a long way to go in just these areas, but decades of growth as we start breaking down more common diseases to actionable subtypes.

We focus on maximizing returns through a focus on companies, developing, selling, making or enabling Precision Medicine. We prefer multi-asset companies and look for barriers to entry, a strong strategy for the whole value chain and sustainable business models. We control the level of risk inherent in development stage companies through individual position sizes and at the portfolio level. Investing in enablers of Precision Medicine is a key part of our portfolio construction process.